FSNUY — Fresenius SE & Co. KGaA
—
OTC ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 904868 ·
Last close
$14.78
Market Cap
$33.30B
52W High
$15.51
52W Low
$10.33
ADV30
174,060
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 5,884,000,000 | 1,533,000,000 | 574,000,000 | 371,000,000 | 42,245,000,000 | 1,715,000,000 | 21,489,000,000 |
| Jun 2026 | 5,945,000,000 | 1,550,000,000 | 632,000,000 | 382,000,000 | 41,844,000,000 | 1,279,000,000 | 21,445,000,000 |
| Mar 2026 | 5,818,000,000 | 1,534,000,000 | 601,000,000 | 435,000,000 | 42,370,000,000 | 2,059,000,000 | 21,905,000,000 |
| Dec 2025 | 6,156,000,000 | 1,524,000,000 | 468,400,000 | 361,000,000 | 41,395,000,000 | 1,307,000,000 | 21,628,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$2,710,000,000
Investing CF
$-197,000,000
Financing CF
$-3,203,000,000
CapEx
$-1,476,000,000
Dividends Paid
$-684,000,000
Buybacks
—
EPS Diluted TTM
$0.67
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
—
Inventory
$2,782,000,000
Receivables
—
ST Investments
$134,000,000
EBIT TTM
$2,727,000,000
Pretax Income TTM
$2,245,000,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$23,281,000,448
EBITDA
$3,039,000,064
Free Cash Flow
$1,710,125,056
Enterprise Value
$40,331,104,256
Total Cash
$1,279,000,064
Total Debt
$11,418,999,808
Shares Out
2,252,949,108
Trailing EPS
$0.81
Book Value
$10.14
ROE
8.3%
ROA
3.4%
Div Yield
2.33%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 22,873,000,000 | 2,181,400,000 | 1,264,000,000 | 41,395,000,000 | 21,628,000,000 | 19,104,000,000 | 2,574,000,000 |
| Dec 2024 | 21,954,000,000 | 2,073,000,000 | 471,000,000 | 43,550,000,000 | 23,260,000,000 | 19,542,000,000 | 2,447,000,000 |
| Dec 2023 | 21,067,000,000 | 1,183,000,000 | -594,000,000 | 45,284,000,000 | 25,633,000,000 | 18,999,000,000 | 4,456,000,000 |
| Dec 2022 | 21,532,000,000 | 1,812,000,000 | 1,372,000,000 | 76,400,000,000 | 44,182,000,000 | 20,415,000,000 | 4,198,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.89
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RMD | RESMED INC | $33.46B | $237.85 | — |
| MDLN | Medline Inc. | $33.11B | $37.68 | — |
| DXCM | DEXCOM INC | $30.60B | $82.04 | — |
| GEHC | GE HealthCare Technologies Inc. | $37.00B | $81.84 | — |
| PHG | KONINKLIJKE PHILIPS NV | $29.22B | $29.89 | — |
News headlines (Yahoo Finance, 1h cache)
mAbxience and OncoPrecision Announce Manufacturing and Investment Agreement for OncoPrecision's ADC Candidate ONC001
2026-11-18 13:00 · Yahoo
Fresenius Kabi Launches Denosumab Biosimilars in Canada, with the First and Only Ready-to-Use Pre-Filled Syringe Biosimilar for Oncology
2026-11-16 13:00 · Yahoo
Is Fresenius SE KGaA (XTRA:FRE) Fairly Valued As Earnings And Its WuXi Deal Lift Interest?
2026-11-11 01:11 · Yahoo
What Akebia Therapeutics (AKBA) Said on Its Q3 Earnings Call
2026-11-05 16:15 · Yahoo
Fresenius SE & Co KGaA (FSNUF) Q3 2026 Earnings Call Highlights: Raised Guidance, Record ...
2026-11-04 23:08 · Yahoo
Fresenius raises 2026 earnings outlook after Q3 profit beats estimates
2026-11-04 06:32 · Yahoo
Fresenius: Q3 Earnings Snapshot
2026-11-03 08:01 · Yahoo
Fresenius and WuXi Bio team up in 37-strong biosimilar development deal
2026-11-02 17:35 · Yahoo
Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline
2026-11-02 06:47 · Yahoo
Is Fresenius SE KGaA (XTRA:FRE) Still A Bargain On Earnings?
2026-11-01 16:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.